| Ytd | 4.61% | |
| 1y | 31.71% |
| Open | 52.20 | Prev Close | 52.42 | Low | 51.08 | High | 52.24 | Mkt Cap | 102.74B |
| Vol | 3.01M | Avg Vol | 3.90M | EPS | 3.75 | P/E | 13.68 | Forward P/E | 10.23 |
| Beta | 0.29 | Short Ratio | 2.24 | Inst. Own | 18.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 05-15 | Earning | 07-28 | 50-d Avg | 51.65 | 200-d Avg | 50.54 | 1yr Est | 56.63 |
Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati
GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late
https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult
GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications:As an
During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst
GSK plc (LSE/NYSE:GSK) today announced that momelotinib, a JAK inhibitor with a differentiated mecha
The Nasdaq 100 sank 3.3% Tuesday as AI and optical stocks cratered, while cash rotated into real est
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares su
Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/o
In times of market turbulence, investors turn to dividend-yielding stocks. Benzinga provides real-ti
GSK partnered with Sino Biopharmaceutical to advance hepatitis B drug bepirovirsen in China while la
Health officials explored restricting specific antidepressants among SSRI drugs-sources
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook
https://www.gov.uk/government/news/mhra-approves-linerixibat-lynavoy-for-the-treatment-of-itch-due-t
Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.
GSK Q1 earnings beat expectations with $10.22B in sales, driven by strong Shingrix vaccine demand. S
2026 guidance and 2031 sales outlook reaffirmed • Expect 2026 turnover growth of between 3% to 5%; C
GSK (NYSE:GSK) reported quarterly earnings of $1.25 per share which beat the analyst consensus estim
AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the la
https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-liver-therapy-efimosfermin-rece
https://www.alfasigma.com/wp-content/uploads/2026/04/Alfasigma-Completes-Agreement-with-GSK-for-line
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty r
FDA court freeze leaves COVID, flu, RSV vaccines in limbo as Kennedy's ACIP overhaul faces legal
https://www.londonstockexchange.com/news-article/GSK/blenrep-approved-in-china-for-2l-multiple-myelo
GSK sees blockbuster potential for Mo-Rez after early trial data shows strong tumor reduction in har
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati
According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals,
https://www.shionogi.com/global/en/news/2026/04/20260401_12.html
https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-china-for-the-treatm
AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock R
Submission supported by statistically significant and clinically meaningful functional cure rates in
Wave Life Sciences stock drops after INLIGHT Phase 1 data. WVE-007 shows fat reduction, lean mass st
https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutat
Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of
A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the
Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership w
FDA expands GSK's Arexvy RSV vaccine approval to high-risk adults aged 18–49, widening access be
GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has expanded t
FDA approves expanded use of Wellcovorin tablets to treat cerebral folate deficiency linked to the F
Submission supported by statistically significant and clinically meaningful functional cure rates de
Submission based on data from positive GLISTEN phase III trialLinerixibat demonstrated significant a
GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary h
Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier Biotech" or "the Com
Merck reports positive RSV trial data, eyes expanded FDA use in children as shares trade near 52-wee
EU approves GSK's Exdensur for severe asthma and nasal polyps, offering twice-yearly dosing and